Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer:
#ESMO24
🔎3-year disease-free survival from NICHE-2
👉💯% DFS
👉all MRD pts cleared ctDNA
🧐Impressive results, ctDNA may be helpful to select for organ preservation
@myESMO#ESMOAmbassadors
@ShikhaJainMD@cvspharmacy I have had the same happen to my patients. Makes your blood boil. There needs to be some alternative- partial fill and office call- something. To leave the patient to go to the ER suffering is absolutely unacceptable on so many levels.
Updated data from the phase 2 OPTIMIZE-1 trial showed that mitazalimab plus mFOLFIRINOX produced encouraging, consistent response rates and a positive signal for DOR in patients with metastatic PDAC. #pancsm#oncology#MedTwitter https://t.co/0i4pbzBOvV
@loconte I just want to be off the phone. Also if they call me David or Mr. David, I just keep going. If you insist to be called Dr. and they refuse- that just seems like they’re being rude and intentionally combative.
@TheNotoriousHPB@JMillerOcuin So sorry Lee. Her memory and all she taught you will live on. I hate pancreatic cancer too- wish there was more we could do….
I'm excited to share that a @UHhospitals & @cwru team - led by a UH Seidman Cancer Center researcher - has developed & validated a 3-in-1 CAR T therapy. This groundbreaking work was featured in the journal Nature Communications. Truly outstanding progress. https://t.co/6V4nGGILOO